choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Thalomid

Thalomid Newsletter
  • Navigating Pharmaceutical Patent Settlements and Reverse Payments: Key Takeaways from the FTC’s Latest MMA Reports 23 Jan 2025 21:41 GMT

    … on pharmaceutical patent settlement agreements filed under the Medicare Prescription Drug, Improvement … 23 agreements involving eight different drug products included quantity restrictions. … ); In re Revlimid & Thalomid Purchaser Antitrust Litig., 2024 U …

  • Myelofibrosis Treatment Options: A Guide for Pharmacists 02 Jan 2025 17:32 GMT

    … thalidomide (Thalomid; Bristol Myers Squibb), and other medications. Treatment for the … enlarged spleen may include targeted drug therapies … contribute significantly to optimizing treatment outcomes. Perhaps most importantly …

  • QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making 12 Nov 2024 22:41 GMT

    … patients and their doctors to work together during treatment decision-making. … frontline treatment. Then, we have three different immunomodulating agents: [Thalomid (thalidomide … need pain medication, whether it’s worth continuing treatment, if they …

  • Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed Myeloma 18 Oct 2024 23:11 GMT

    … Darzalex) plus bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (D-VTd) in … may benefit from intensified treatment. Additionally, the trial highlights the value … phase 3 MIDAS trial (NCT04934475), which adjusts treatment with another quadruplet …

  • Dr Corre on the Rationale for the CASSIOPEIA Trial in Newly Diagnosed Myeloma 17 Oct 2024 21:05 GMT

    … CASSIOPEIA trial (NCT02541383) of daratumumab (Darzalex) plus bortezomib (Velcade), thalidomide (Thalomid), … disease (MRD) negativity following treatment with induction and consolidation D … The trial has established D-VTd as a standard treatment for newly …

  • To Reduce Drug Prices, Issue Fewer Weak Patents 22 Jun 2024 22:13 GMT

    … abetting monopoly power in the pharmaceutical industry. I describe numerous examples … ” to ensure that its myeloma drug Thalomid wasn’t used in pregnant … birth defects), Celgene patented the FDA-mandated strategy, rendering it impossible …

  • Remembering Dr. Frances Kelsey, B.C.’s American medical hero 04 Jun 2024 17:08 GMT

    … names Conterganand Thalomid, and was an oral medication used to … her to get an honourary doctorate through VIU [Vancouver Island … a lot with anti-malarial drugs. Treating malaria with quinine … Frances Oldham Kelsey, the FDA, and the Battle against Thalidomide …

  • 2023 First Generic Drug Approvals 08 Mar 2024 22:36 GMT

    … Package B. Braun Medical, Inc. Calcium Gluconate … refractory to other drugs 18 213267 Thalidomide … Thalomid (Thalidomide) Capsules 4/27/2023 For the treatment … 0.064% Glenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited Enstilar ( …

  • Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma 19 Jan 2024 22:15 GMT

    … or MRD) after treatment. Findings from the trial, called PERSEUS, were … the drug cocktail, swapping out or adding in new medicines … these kinds of phase 3 trials [for] multiple myeloma,” … , dexamethasone, and thalidomide (Thalomid). And other options may …

  • Bristol Myers to Acquire the Drugmaker Karuna for $14 Billion 22 Dec 2023 17:55 GMT

    … Myers Squibb, the global pharmaceutical giant, said on Friday … Therapeutics, which makes drugs to treat schizophrenia and … Cerevel Therapeutics, which develops drugs to treat psychiatric and … of the blockbuster Thalomid and Revlimid cancer medicines, for $74 …

Satisfied with the content?

Continue to create your account.